Literature DB >> 25492370

Still no certainty about the role of upfront bortezomib among patients with AL amyloidosis.

A Dispenzieri1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25492370     DOI： 10.1038/leu.2014.271

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

1.  Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.

Authors:  Angela Dispenzieri; Morie A Gertz; Robert A Kyle; Martha Q Lacy; Mary F Burritt; Terry M Therneau; Joseph P McConnell; Mark R Litzow; Dennis A Gastineau; Ayalew Tefferi; David J Inwards; Ivana N Micallef; Stephen M Ansell; Luis F Porrata; Michelle A Elliott; William J Hogan; S Vincent Rajkumar; Rafael Fonseca; Philip R Greipp; Thomas E Witzig; John A Lust; Steven R Zeldenrust; Denise S Snow; Susan R Hayman; Christopher G A McGregor; Allan S Jaffe
Journal:  Blood       Date:  2004-03-25       Impact factor: 22.113

2.  High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis.

Authors:  A Dispenzieri; M A Gertz; S K Kumar; M Q Lacy; R A Kyle; A K Saenger; M Grogan; S R Zeldenrust; S R Hayman; F Buadi; P R Greipp; N Leung; S R Russell; D Dingli; J A Lust; S V Rajkumar; A S Jaffe
Journal:  Heart       Date:  2014-01-08       Impact factor: 5.994

3.  Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study.

Authors:  Donna E Reece; Ute Hegenbart; Vaishali Sanchorawala; Giampaolo Merlini; Giovanni Palladini; Joan Bladé; Jean-Paul Fermand; Hani Hassoun; Leonard Heffner; Robert A Vescio; Kevin Liu; Christopher Enny; Dixie-Lee Esseltine; Helgi van de Velde; Andrew Cakana; Raymond L Comenzo
Journal:  Blood       Date:  2011-05-11       Impact factor: 22.113

4.  A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.

Authors:  Ashutosh D Wechalekar; Stefan O Schonland; Efstathios Kastritis; Julian D Gillmore; Meletios A Dimopoulos; Thirusha Lane; Andrea Foli; Darren Foard; Paolo Milani; Lisa Rannigan; Ute Hegenbart; Philip N Hawkins; Giampaolo Merlini; Giovanni Palladini
Journal:  Blood       Date:  2013-03-11       Impact factor: 22.113

5.  A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis.

Authors:  C P Venner; J D Gillmore; S Sachchithanantham; S Mahmood; T Lane; D Foard; L Rannigan; S D J Gibbs; J H Pinney; C J Whelan; H J Lachmann; P N Hawkins; A D Wechalekar
Journal:  Leukemia       Date:  2014-07-16       Impact factor: 11.528

6.  Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.

Authors:  Donna E Reece; Vaishali Sanchorawala; Ute Hegenbart; Giampaolo Merlini; Giovanni Palladini; Jean-Paul Fermand; Robert A Vescio; Xiangyang Liu; Yusri A Elsayed; Andrew Cakana; Raymond L Comenzo
Journal:  Blood       Date:  2009-06-04       Impact factor: 22.113

7.  Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients.

Authors:  G Palladini; P Milani; A Foli; M Vidus Rosin; M Basset; F Lavatelli; M Nuvolone; L Obici; S Perlini; G Merlini
Journal:  Leukemia       Date:  2014-07-25       Impact factor: 11.528

8.  Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.

Authors:  Joseph R Mikhael; Steven R Schuster; Victor H Jimenez-Zepeda; Nancy Bello; Jacy Spong; Craig B Reeder; A Keith Stewart; P Leif Bergsagel; Rafael Fonseca
Journal:  Blood       Date:  2012-02-13       Impact factor: 22.113

9.  Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.

Authors:  Christopher P Venner; Thirusha Lane; Darren Foard; Lisa Rannigan; Simon D J Gibbs; Jennifer H Pinney; Carol J Whelan; Helen J Lachmann; Julian D Gillmore; Philip N Hawkins; Ashutosh D Wechalekar
Journal:  Blood       Date:  2012-02-13       Impact factor: 22.113
  9 in total
  1 in total

1.  Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis.

Authors:  Chihiro Shimazaki; Shin-Ichi Fuchida; Kenshi Suzuki; Tadao Ishida; Hirokazu Imai; Morio Sawamura; Hiroyuki Takamatsu; Masahiro Abe; Toshihiro Miyamoto; Hiroyuki Hata; Masahito Yamada; Yukio Ando
Journal:  Int J Hematol       Date:  2015-11-20       Impact factor: 2.490
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.